Multiple treatment options are available for the management of metastatic prostate cancer beyond ADT, including chemotherapy, radiopharmaceuticals, immunotherapy, and agents targeting androgen receptor (AR) signaling. Here, AR is linked to metastatic prostate carcinoma.